In contemporary US practice, P2Y12 inhibitor pretreatment before invasive evaluation of coronary artery disease is low (27.8%), reflecting variable practice patterns and a lack of definitive guideline consensus.
No takes yet. Share an insight, caveat, or question.
Highlights variable US practice without consensus; leaves open need for outcome trials on optimal P2Y12 pretreatment timing.
Fan et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: